The success achieved in the management of children with acute lymphoblastic leukemia has now been extended to older adolescents and young adults, as demonstrated recently by Nachman and coauthors. The effectiveness of treatment with an intense multiagent chemotherapy protocol renders the use of allogeneic hematopoietic stem-cell transplantation in first remission questionable, and calls for careful evaluation of the use of this chemotherapy in this patient population.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Goldstone, A. H. et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111, 1827–1833 (2008).
Balduzzi, A. et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 366, 635–642 (2005).
Bleyer, W. A. et al. Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med. Pediatr. Oncol. 38, 1–10 (2002).
Ferrari, A., Montello, M., Budd, T. & Bleyer, A. The challenges of clinical trials for adolescents and young adults with cancer. Pediatr. Blood Cancer 50, 1101–1104 (2008).
Boissel, N. et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J. Clin. Oncol. 21, 774–780 (2003).
de Bont, J. M. et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 18, 2032–2035 (2004).
Stock, W. et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 112, 1646–1654 (2008).
Ribera, J. M. et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia Pediatric-Based Protocol ALL-96. J. Clin. Oncol. 26, 1843–1849 (2008).
Nachman, J. B. et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive post-induction treatment: a report from the Children's Oncology Group. J. Clin. Oncol. 27, 5189–5194 (2009).
Seibel, N. L. et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report form the Children's Oncology Group. Blood 111, 2548–2555 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Hutchinson, R. Improved outcome for young adult patients with ALL. Nat Rev Clin Oncol 7, 132–134 (2010). https://doi.org/10.1038/nrclinonc.2010.14
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.14
